Vimseltinib

Vimseltinib
Clinical data
Trade names	Romvimza
AHFS/Drugs.com	Monograph
MedlinePlus	a625067
License data	US DailyMed: Vimseltinib;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one;
CAS Number	1628606-05-2;
PubChem CID	86267612;
IUPHAR/BPS	11190;
DrugBank	DB17520;
ChemSpider	95499700;
UNII	PX9FTM69BF;
KEGG	D12238;
ChEMBL	ChEMBL5095202;
Chemical and physical data
Formula	C23H25N7O2
Molar mass	431.500 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C;
	InChI InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27); Key:TVGAHWWPABTBCX-UHFFFAOYSA-N;

Vimseltinib, sold under the brand name Romvimza, is an anti-cancer medication used for the treatment of tenosynovial giant cell tumor.^[1]^[2] Vimseltinib is a kinase inhibitor.^[1]^[2] Vimseltinib is a macrophage colony-stimulating factor receptor antagonist.^[3]

The most common adverse reactions, including laboratory abnormalities, include increased aspartate aminotransferase, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutrophils, decreased leukocytes, pruritus, and increased alanine aminotransferase.^[2]

Vimseltinib was approved for medical use in the United States in February 2025.^[2]^[4]

^ ^a ^b ^c "Romvimza- vimseltinib capsule". DailyMed. 18 February 2025. Retrieved 3 March 2025.
^ ^a ^b ^c ^d "FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor". U.S. Food and Drug Administration (FDA). 14 February 2025. Archived from the original on 14 February 2025. Retrieved 16 February 2025. This article incorporates text from this source, which is in the public domain.
^ Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, et al. (October 2022). "Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)". Bioorganic & Medicinal Chemistry Letters. 74: 128928. doi:10.1016/j.bmcl.2022.128928. PMID 35961460.
^ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 21 February 2025. Archived from the original on 3 March 2025. Retrieved 9 March 2025.

[Romvimza_FDA_label-1] "Romvimza- vimseltinib capsule". DailyMed. 18 February 2025. Retrieved 3 March 2025.

[FDA_vimseltinib-2] "FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor". U.S. Food and Drug Administration (FDA). 14 February 2025. Archived from the original on 14 February 2025. Retrieved 16 February 2025. This article incorporates text from this source, which is in the public domain.

[Caldwell_2022-3] Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, et al. (October 2022). "Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)". Bioorganic & Medicinal Chemistry Letters. 74: 128928. doi:10.1016/j.bmcl.2022.128928. PMID 35961460.

[4] "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 21 February 2025. Archived from the original on 3 March 2025. Retrieved 9 March 2025.

[1]

[2]

[3]

[4]